DNA-based nano-sized systems for pharmaceutical and biomedical applications.
DNA is one of the most important components for all living organisms and many species, including humans, use DNA to store and transmit genetic information to new generations. Recent advances in the handling of DNA have made it possible to use DNA as a building block of nano-sized materials with precisely designed architectures. Although various approaches have been proposed to obtain DNA assemblies with designed architecture in the nano- to micrometer range, there is little information about their interaction with biological components, including target molecules. Understanding the interaction between DNA assemblies and the body is highly important for successful pharmaceutical and biomedical applications. Here, we first review the basic aspects of externally administered DNA molecules, including the stability, permeability and delivery issues. Then, we discuss the unique responses observed in the interaction of structured DNA assemblies and cells expressing Toll-like receptor-9, the receptor responsible for the recognition of unmethylated CpG dinucleotides that are abundant in the DNA of invading pathogens, such as bacteria and viruses.
Department of Biopharmaceutics and Drug Metabolism, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan. makiya@pharm.kyoto-u.ac.jp
Makiya
M
Nishikawa
Sakulrat
S
Rattanakiat
Yoshinobu
Y
Takakura
D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000627:therapeutic use; D004247:DNA / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D004337:Drug Carriers; D006801:Humans; D008968:Molecular Conformation; D053758:Nanoparticles / Q000627:therapeutic use* / Q000648:ultrastructure; D036103:Nanotechnology; D009690:Nucleic Acid Conformation; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D004337:Drug Carriers; D009838:Oligodeoxyribonucleotides; D004247:DNA